At the World Biosimilar Congress, the industry in attendance are fiercely aware of the impact biosimilar drugs have on patient populations. Whether it’s about making a life extending drug available to a few more people, or enabling the criteria for who receives these costly products to widen, the patient is always front of mind. For the past three years, we’ve been proud to be a part of an industry that is working tirelessly to bring cost-effective biologic drugs to patients.In 2015, the World Biosimilar Congress is going one step further. One of the biggest problems for this important field is end-user uptake. For the industry to succeed, it’s vital that physicians, nurses and medical staff are educated in interchangeability and extrapolation issues. It’s important that patient advocacy groups are aware of the impact of biosimilar drugs and are prepared to fight for them. And that payers really understand the benefits of their adoption. In 2015, we’re excited to bring all of these stakeholders together with industry for an explosive two days.Key topics for 2015:• Overcoming Developmental Challenges of Biosimilars• Extrapolation & Interchangeability• Preclinical and Clinical Development• Regulatory Guidelines on Biosimilars• Legal and Financial Considerations for Biosimilars• Labelling and Naming Conventions• Healthcare Uptake